anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A loricrin constitutive vector for efficient expression of a nucleic acid sequence in epidermal cells comprising the 5' flanking region of the loricrin gene, said flanking region containing a TATA box, a cap site and a first intron and intron/exon boundary all in appropriate sequential and positional relationship for expression of a nucleic acid cassette, a 3' flanking sequence of the loricrin gene and a linker containing a unique restriction endonuclease site at the location of the start and stop codon. Said linker connecting the 5' flanking region to the 3' flanking sequence and said linker further providing a position for inserting the cassette. The cassette contains the specific nucleic acid sequence to be expressed. Also, there is a keratin K6 inducible vector for regulating expression of a nucleic acid sequence in epidermal cells comprising the 5' flanking region of the keratin K6 gene, said flanking region including the TATA box, a cap site and the first intron and intron/exon boundary all in sequential and positional relationship for expression of a nucleic acid cassette, a 3' flanking sequence of the keratin K6 gene, and a polylinker having a plurality of restriction endonuclease sites. The polylinker connects the 5' flanking region to the 3' flanking sequence and further provides a position for insertion of the cassette. The keratin K6 and loricrin vectors can be further regulated by the addition of a Vitamin D regulatory element. The vectors can be used in a bioreactor for generating a variety of products including proteins, polypeptides or antisense RNAs. The vectors can also be used for gene therapy in treatment of a variety of diseases in animals and humans including wound healing, surgical incisions, skin ulcers, psoriasis and skin cancer, and in vaccination.
Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
Lung transplant recipients with pre-transplant serological immunity to CMV. CMV-TCIP will be measured every 3 months post-transplant with antiviral prophylaxis discontinued when threshold is exceeded.
FIELD: medicine. SUBSTANCE: in a lesion focus one should carry out a subcutaneous puncturing with ozone-oxygen mixture at 2-4 mcg/ml ozone concentration and 0.3-0.5 cm 3  volume per one injection once weekly and cryomassage, 10-20 seances, totally, and between puncturings - an extensive autohemoozonotherapy at 3-10 mcg/ml ozone concentration once or twice weekly. Additionally, it is possible to intracutaneously inject a homeopathic cocktail into a lesion focus to enhance circulation, not less than 10, totally. The above- mentioned cocktail includes both coenzyme Q and placenta compositum. Therapy courses should be repeated twice or thrice at 2-3-mo-long intervals. EFFECT: higher efficiency of therapy. 3 cl
Compsn. comprises a protease resistant single-chain urokinase (I). (I) may be prepd. by (a) providing nucleic acid encoding a protease-resistant amino acid sequence variant of single-chain urokinase, (b) transforming a host cell with the nucleic acid, (c) culturing the transformed host cell until the variant urokinase accumulates in the culture and (d) recovering the variant urokinase from the culture. (I) is produced by combining urokinase with an agent to complex with urokinase or by covalently modifying single-chain urokinase at sites of proteolysis. The target sites include Arg156 to Lys158 and, pref., the site at residues Lys135 to Lys136. Covalent modifications are accomplished by reacting native urokinase with derivatising reagents or by the recombinant synthesis of mutants having site specific substns., insertions or deletions of amino acid residues at target sites. Complexing agents such as antibodies bind to urokinase at the target sites or at flanking sites so that access to the sites by proteases is impeded or prevented.
Approximately 12% of human cancers worldwide are associated with infectious agents, which are classified by the International Agency for Research on Cancer (IARC) as Group 1 within the agents that are carcinogenic to humans. Most of these agents are viruses. Group 1 oncogenic viruses include hepatitis C virus, hepatitis B virus (HBV), human T-cell lymphotropic virus type 1, Epstein-Barr virus, Kaposi sarcoma-associated herpesvirus, human immunodeficiency virus-1 and high-risk human papillomaviruses (HPVs). In addition, some human polyomaviruses are suspected of inducing cancer prevalently in hosts with impaired immune responses. Merkel cell polyomavirus has been associated with Merkel cell carcinoma and included by the IARC in Group 2A (i.e., probably carcinogenic to humans). Linking viruses to human cancers has allowed for the development of diagnostic, prophylactic and therapeutic measures. Vaccination significantly reduced tumours induced by two oncogenic viruses as follows: HBV and HPV. Herein, we focus on mucosal alpha HPVs, which are responsible for the highest number of cancer cases due to tumour viruses and against which effective prevention strategies have been developed to reduce the global burden of HPV-related cancers.
After administration of lidocaine and atropine sulfate, and also preoxygenation (100% 4 L/min oxygen for 3 min), patients will be induced with propofol and fentanyl. After induction of anesthesia, supraglottic airway device named Gastro-laryngeal Tube (GLT) will be inserted. Patients will be ventilated mechanically with a tidal volume of 6-8 mL/kg based on ideal body weight and a frequency of 12-14 breaths/min after inserting the GLT. Repetitive intravenous boluses of propofol will be administered, if required.
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.
The investigators propose an open label trial to assess the safety of using electrical stimulation at acupuncture sites in 42 infants receiving a routine heel stick. Two sub studies will precede the main safety study, with 6 infants in each sub study and 30 infants in the main study. These sub studies will use electrical stimulation intensities that are a fraction of the planned intensity of the electrical stimulation that will be used for the main part of the study.

As part of routine neonatal screening, blood will be collected from a heel stick(s) by qualified nursing staff in the hospital nursery or in the patient's room. Less than one ml of blood will be drawn over 1-2 minutes. Study infants will be watched more carefully with heart rate, respiratory rate, and oxygen saturation performed as part of this study. Infants not participating in the study will be watched as per usual unit protocol.

Electrical stimulation at acupuncture sites will be administered via an EMPI Select Transcutaneous Electrical Nerve Stimulation (TENS) unit. To produce analgesia, small electrodes will be placed on the baby's legs at specific acupuncture points: ZuSanLi (ST36) just below the knee, triggers release of endorphins; SanYinJiao (SP6) just above the inner ankle, important point for energy balance; Kun Lun (BL60) depression behind lateral malleolus, protects local tissue trauma to heel; and Tai Xi (Ki3) behind the inner ankle, an important energy meridian. 25, 39, 48-50, StimCare self-adhesive electrodes with a gel base will be applied to the skin; the skin will not be punctured by these procedures. For the main part of the study, a low continuous current will be provided with minimal voltage of 3.5 milliamps (mA). The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heelstick. This paradigm is based on the basic animal research developed by Dr. Han and other research groups. Two sub studies will precede the main safety study, with 6 infants in each sub study, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
A buforin derivative kaisin, kaisin I and kaisin II are provided to act selectively on cancer cells without acting on normal cells, thereby capable of providing an anticancer agent with excellent anti-cancer activity. An anticancer agent comprises a buforin derivative kaisin having an amino acid sequence of SEQ ID : NO. 1, a buforin derivative kaisin I having an amino acid sequence of SEQ ID : NO. 2, or a buforin derivative kaisin II having an amino acid sequence of SEQ ID : NO. 3 as an effective ingredient. The anticancer agent further comprises a pharmaceutically acceptable carrier.
The invention discloses a 3,3'-hydroxy curcumin analogue and a preparation method and application thereof. Please see the structural formula of the 3,3'-hydroxy curcumin analogue in the specification. The preparation method of the curcumin analogue includes the following steps that under the condition of boron oxide/ tributyl borate/n-butylamine, hydroxybenzaldehyde and acetylacetone are condensed so that the 3,3'-hydroxy curcumin analogue can be obtained. The curcumin analogue is used for drug therapy of lever cancer. Raw materials of the curcumin analogue are easy to obtain, the molecular structure of the product is simple, the preparation technology is simple, the reaction condition is moderate, and the 3,3'-hydroxy curcumin analogue is suitable for industrial production. The inhibitory activity of the curcumin analogue on proliferation of the liver cancer cell HepG2 is superior to natural product curcumin. The curcumin analogue has important significance in discovery of guiding pro-drugs and design of lead compounds.
BACKGROUND: Tumor-associated macrophages (TAMs) play an important role in the recurrence and progression of clear cell renal cell carcinoma (ccRCC). However, the specified mechanism has not been elucidated.
METHODS: Single-cell and transcriptome analysis were applied to characterize the heterogeneity of TAMs. SCENIC would infer regulators of different subsets of TAMs. The CellChat algorithm was used to infer macrophage-tumor interaction networks, whereas pseudo-time traces were used to parse cell evolution and dynamics.
RESULTS: In this study, single-cell transcriptomic data of ccRCC were analyzed. Notably, the macrophages were clustered to select the cluster with a tendency toward M2-type TAM, which has an impact on the occurrence and metastasis of ccRCC. This macrophage cluster was defined as "TAM2". And this study revealed that TCF7L2 as a potential transcription factor regulating TAM2 transcriptional heterogeneity and differentiation. Pseudotime traces showed TCF7L2 trajectories during TAM2 cell cluster development. In addition, the results of cell interaction showed that TAM2 had the highest number and strength of interactions with cancer cells and endothelial cells. In vitro experiments, this study found that TCF7L2 was highly expressed in TAMs and promoted the polarization of macrophages to M2-type macrophages. And then overexpression of TCF7L2 in macrophages markedly promoted ccRCC invasion and proliferation.
CONCLUSION: TCF7L2 could play a key role in the progression of ccRCC via enhancing TAMs recruitment and M2-type polarization.
The experimental group will receive the self-applied intervention through a digital platform. The intervention consists of three stages, depending on the situation of the patient: 1) Patients who undergo screening and obtain negative results for malignancy, 2) patients with suspicion and undergo a biopsy, 3) Patients with positive results for breast cancer.
Tissue regeneration is limited in several organs, including the kidney, contributing to the high prevalence of kidney disease globally. However, evolutionary and physiological adaptive responses and the presence of renal progenitor cells suggest an existing remodeling capacity. This study uncovered endogenous tissue remodeling mechanisms in the kidney that were activated by the loss of body fluid and salt and regulated by a unique niche of a minority renal cell type called the macula densa (MD). Here, we identified neuronal differentiation features of MD cells that sense the local and systemic environment and secrete angiogenic, growth, and extracellular matrix remodeling factors, cytokines and chemokines, and control resident progenitor cells. Serial intravital imaging, MD nerve growth factor receptor and Wnt mouse models, and transcriptome analysis revealed cellular and molecular mechanisms of these MD functions. Human and therapeutic translation studies illustrated the clinical potential of MD factors, including CCN1, as a urinary biomarker and therapeutic target in chronic kidney disease. The concept that a neuronally differentiated key sensory and regulatory cell type responding to organ-specific physiological inputs controls local progenitors to remodel or repair tissues may be applicable to other organs and diverse tissue-regenerative therapeutic strategies.
PURPOSE:To secrete drug effective substances and other active constituents from plant bodies in a state of the living plant bodies in a culture fluid and recover effectively and continuously the active constituents, by subjecting the plants containing the active constituents therein to the nutriculture. CONSTITUTION:A plant, e.g. Coptis japonica Makino, Gentiana scabra var. orientalis Hara, Geranium nepalense var. thunbergii or Panax ginseng C.A. Meyer, is grown by the nutriculture. In the process, any of water culture, spray culture, solid medium culture and electric methods may be applied to the nutriculture. A culture fluid is suitably collected in a suitable period, e.g. 10 days or one month, during the growth period, and medicinal substances and other active constituents are recovered from the culture fluid. A suitable combination of one or two or more of an enzyme including cellulase or hemicellulase, organic solvent, organic synthetic high polymer and surfactant added to the culture fluid of the nutriculture promotes the secretion of the above-mentioned medicinal substances, and acts as a secretion promoter to improve remarkably the yield.
Methods for manufacturing remotely custom fit dental orthotics, where a wearer makes impressions of their upper and lower teeth and also makes a bite impression that determines the relationship of the upper teeth to the lower teeth, preferably in an orthopedically optimized position with respect to each other. The impressions and bite registration are sent by the wearer to a manufacturing facility in a different location. At the manufacturing facility, the impressions are used to make models of the wearer's upper and lower teeth. The models are mounted on an articulator, and the bite registration is used to position the mounted models in the orthopedically optimized position which is locked in to the articulator. The bite registration is removed and a dental orthotic customized to the wearer and the orthopedically optimized position is formed between the models. The custom orthotic is then sent to the wearer.
UNLABELLED: Congenital pectus excavatum (PE) takes the first place among the deformation of the chest, accompanied by violations of the cardiorespiratory system and various cosmetic defects. A radical way to eliminate the deformation of the chest is surgical correction-thoracoplasty.
MATERIAL AND METHODS: This study was performed on the results of surgical treatment of 183 patients with various forms of PE at the age of 3 to 18 years. All operated children were divided into three groups. The first group consisted of 76 (41.5%) patients who underwent thoracoplasty with fixation of the mobilized sternal-rib complex on an external traction splint. The second group included 77 (42,1%) patients operated by the developed method of thoracoplasty. The third group of 30 (16.4%) patients operated on the classical Nuss-method. Short- and long-term results were compared between the groups.
RESULTS: The operation time was significantly shorter in third group (55 min) and the volume of blood loss was higher in the first group (46,4±12,5 ml). Pleural effusion and atelectasis were observed 4 and 3 patients and atelectasis, or pneumonitis was observed 3 and 2 patients in first and third groups respectively. The duration of postoperative pain syndrome was significantly shorter in second group with intercostal blockade. Pneumothorax was established 4 and 3 patients in first and third groups. Partial relapse and complete relapse were observed 3 (4.1%) and 2 (2.7%) patients in the first group.
CONCLUSION: Short and long-term results were excellent for modified thoracoplasty and Nuss procedures with low complication rates.
Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
Project ASTHMA in schools is a 7 month randomized control intervention pilot trial. Forty students, ages 4 to 14 years, with persistent asthma, or who utilize acute care facilities frequently for their asthma, will be recruited from 3 urban SBHCs in the fall of 2018. All students will receive NHLBI guideline-based asthma assessments to determine eligibility and proper dosing of preventive medication. The asthma assessment will include spirometry testing. All enrolled students and parents will receive asthma education at the time of enrollment. Eligible students will be randomized to an intervention or usual care group using permuted block randomization stratified by SBHCs. In collaboration with the student's PCP, the SBHCs' mid-level providers will prescribe the preventive medication to the students in the intervention group. These students will receive the morning dose of their preventive medication from the school nurse each school day for the remainder of the school year. Students and their parents will be responsible to administer the evening and non-school day doses. Students randomized to the usual care group will be referred back to their PCP for further asthma management. All participants will be re-evaluated at 1, 3 and 7 months after enrollment, and medication dose adjustments will be made in the intervention group as needed.
Pharmacokinetic information of diazepam following rectal administration was obtained from studies conducted in healthy adult subjects. No pharmacokinetic studies were conducted in pediatric patients. Therefore, information from the literature is used to define pharmacokinetic labeling in the pediatric population.

Diazepam rectal gel is well absorbed following rectal administration, reaching peak plasma concentrations in 1.5 hours. The absolute bioavailability of diazepam rectal gel relative to Valium injectable is 90%. The volume of distribution of diazepam rectal gel is calculated to be approximately 1 L/kg. The mean elimination half-life of diazepam and desmethyldiazepam following administration of a 15 mg dose of diazepam rectal gel was found to be about 46 hours (CV=43%) and 71 hours (CV=37%), respectively.   
Both diazepam and its major active metabolite desmethyldiazepam bind extensively to plasma proteins (95-98%). 

FIGURE 1:Plasma Concentrations of Diazepam and Desmethyldiazepam Following Diazepam Rectal Gel or IV Diazepam 

Metabolism and Elimination:It has been reported in the literature that diazepam is extensively metabolized to one major active metabolite (desmethyldiazepam) and two minor active metabolites, 3-hydroxydiazepam (temazepam) and 3-hydroxy-N-diazepam (oxazepam) in plasma. At therapeutic doses, desmethyldiazepam is found in plasma at concentrations equivalent to those of diazepam while oxazepam and temazepam are not usually detectable. The metabolism of diazepam is primarily hepatic and involves demethylation (involving primarily CYP2C19 and CYP3A4) and 3-hydroxylation (involving primarily CYP3A4), followed by glucuronidation. The marked inter-individual variability in the clearance of diazepam reported in the literature is probably attributable to variability of CYP2C19 (which is known to exhibit genetic polymorphism; about 3-5% of Caucasians have little or no activity and are “poor metabolizers”) and CYP3A4. No inhibition was demonstrated in the presence of inhibitors selective for CYP2A6, CYP2C9, CYP2D6, CYP2E1, or CYP1A2, indicating that these enzymes are not significantly involved in metabolism of diazepam.
The invention discloses a method for improving the triterpene output of Ganoderma lucidum liquid fermented mycelia by a traditional Chinese medicinal extract. In the invention, liquid culture is employed for culturing Ganoderma lucidum mycelia. During liquid fermentation of the Ganoderma lucidum mycelia, a culture medium containing the traditional Chinese medicinal extract is adopted for liquid fermentation culture of the Ganoderma lucidum mycelia. Traditional Chinese medicinal extracting solutions (e.g. radix isatidis, forsythia, rhizoma alismatis, radix astragali, and spina date seeds) of different concentrations are added into the Ganoderma lucidum liquid culture medium for inoculation culture, after which the triterpene output of the Ganoderma lucidum mycelia can be determined to have substantial improvement. The method of the invention has the advantages of low cost, no pollution, and easy realization of industrial production, etc.
1,167,221. Pharmaceutical liver/spleen extracts. INSTITUTO BIOTERAPICO GENOVESE S.p.A. 5 Jan., 1967, No. 781/67. Heading A5B. A cardioactive material is obtained from the liver and spleen of freshly slaughtered mammals by the following procedure. The organs are together homogenised, dispersed in water buffered at pH 6.0 and oxygen is removed e.g. by bubbling gaseous N 2  through the suspension and maintaining it under a nitrogen atmosphere. After 24 hours, the temperature is raised to 37‹C for 48 hours to llow autodigestion to take place. The solid is emoved and subjected to the same procedure twice more and the aqueous fractions are pooled and concentrated under vacuum to an S.G. of 1.1425 at 15‹C. Ethyl alcohol is added and, after standing at 0‹C., the solid residue is discarded and the ethanol is removed from the aqueous fraction, which is reconcentrated to the above S.G. The concentrate is washed with ether and passed through a carboxylic cation exchange resin column. The effluent is concentrated (to S.G. 1.1425), its pH is adjusted to 6.5, phenol is added (to 3% w/v) and the extract is stored at -5‹C. for 3 months. Thereafter, it is filtered, washed with ether and stored at 0‹C. until used. Preferably, the extract is used in combination with dry myocardium extract and corticosupra-renal extract in the treatment (by injection) and coronary insufficiency and arhythma.